Autonomix Medical, Inc. (AMIX)
NASDAQ: AMIX · Real-Time Price · USD
1.155
-0.045 (-3.75%)
Aug 11, 2025, 1:33 PM - Market open
CEQP Employees
As of March 31, 2025, Autonomix Medical had 11 total employees, including 8 full-time and 3 part-time employees. The number of employees increased by 3 or 37.50% compared to the previous year.
Employees
11
Change (1Y)
3
Growth (1Y)
37.50%
Revenue / Employee
n/a
Profits / Employee
-$1,037,273
Market Cap
3.21M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 11 | 3 | 37.50% |
Mar 31, 2024 | 8 | 4 | 100.00% |
Mar 31, 2023 | 4 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AMIX News
- 20 days ago - Autonomix Medical, Inc. Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference - GlobeNewsWire
- 21 days ago - Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications - GlobeNewsWire
- 5 weeks ago - Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment - GlobeNewsWire
- 6 weeks ago - Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study - GlobeNewsWire
- 6 weeks ago - Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology - GlobeNewsWire
- 2 months ago - Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain - GlobeNewsWire
- 3 months ago - Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology - GlobeNewsWire
- 3 months ago - Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event - GlobeNewsWire